Posts by DCprime


HomeDCprime

DCprime and Radboudumc to collaborate

Leiden, The Netherlands and Nijmegen, The Netherlands, March 2019– DCprime and Radboudumc announce that they will collaborate as part of a public-private consortium supported by The Dutch Top Sector Life Sciences and Health, represented by Stichting Life Sciences Health – TKI, also acting under its trade name Health~Holland, under the project title “Dendritic Cell Targeting


Jeroen Rovers MD, PhD joins DCprime as Chief Medical Officer

Leiden, The Netherlands, October 01, 2018 – DCprime announces today that Jeroen Rovers MD, PhD joins the company as its Chief Medical Officer with immediate effect. Jeroen trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 15 years he worked in different academic institutes and companies, lastly


DCprime and Glycotope announce licensing agreement and collaboration

    DCprime and Glycotope announce licensing agreement and collaboration Leiden, The Netherlands, and Berlin, Germany, 18 July 2018 – DCprime bv, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, announce today that they have entered into a license agreement


DCprime announces that Erik Manting PhD will join the company as its CEO

Leiden, The Netherlands, March 01, 2018 – DCprime announces today that Erik Manting PhD will become DCprime’s new Chief Executive Officer with immediate effect. Dr Manting succeeds Ada Kruisbeek, who will remain committed to DCprime as Chief Scientific Officer. Prior to joining DCprime, Erik spent 15 years in different management and commercial roles, of which


DCOne® induces immune responses against Multiple Myeloma

Leiden, The Netherlands – DCPrime B.V., a clinical stage company dedicated to developing cancer vaccines based on its proprietary DCOne® platform, announces the publication of a peer-reviewed research paper which documents that its lead product DCP-001 can induce T cell activation and myeloma-specific immunity in peripheral blood mononuclear cells from patients with Multiple Myeloma (MM).


DCPrime and apceth Biopharma GmbH announce manufacturing partnership

Leiden, The Netherlands, and Munich, Germany – DCPrime BV, a clinical stage company developing dendritic cell vaccines to treat cancer, and apceth Biopharma GmbH, an established contract manufacturing organization in the field of gene and cell therapy, report today that they have entered into a strategic manufacturing agreement. The collaboration involves clinical batch production and


DCPrime obtains patent protection for DCOne® platform

DCPrime obtains broad patent protection in the EU for proprietary DCOne® platform. DCPrime, a clinical stage cancer immunotherapy company, has been granted a European patent on its DCOne® platform. The patent covers its proprietary cell line DCOne®, the accompanying methods for obtaining mature dendritic cells, and the mature dendritic cells which are obtainable by this method,